New Risk • May 05
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.1% Last year net profit margin: 7.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Announcement • Mar 31
Guanhao Biotech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Guanhao Biotech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Reported Earnings • Mar 27
Full year 2025 earnings released: EPS: CN¥0.09 (vs CN¥0.10 in FY 2024) Full year 2025 results: EPS: CN¥0.09 (down from CN¥0.10 in FY 2024). Revenue: CN¥387.7m (up 2.7% from FY 2024). Net income: CN¥24.3m (down 11% from FY 2024). Profit margin: 6.3% (down from 7.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. New Risk • Mar 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results. Announcement • Mar 25
Guanhao Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2026 Guanhao Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China New Risk • Jan 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Announcement • Dec 31
Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 26, 2026 Guanhao Biotech Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 26, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.022 (vs CN¥0.023 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.022 (down from CN¥0.023 in 3Q 2024). Revenue: CN¥92.6m (up 4.7% from 3Q 2024). Net income: CN¥6.31m (down 18% from 3Q 2024). Profit margin: 6.8% (down from 8.7% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Guanhao Biotech Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Guanhao Biotech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Reported Earnings • Aug 28
Second quarter 2025 earnings released: EPS: CN¥0.021 (vs CN¥0.027 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.021 (down from CN¥0.027 in 2Q 2024). Revenue: CN¥106.1m (up 8.0% from 2Q 2024). Net income: CN¥5.54m (down 3.8% from 2Q 2024). Profit margin: 5.2% (down from 5.9% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Jul 02
Guanhao Biotech Co.,Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Guanhao Biotech Co.,Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • May 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Large one-off items impacting financial results. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.06 (vs CN¥0.05 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.06 (up from CN¥0.05 in 1Q 2024). Revenue: CN¥94.8m (up 3.7% from 1Q 2024). Net income: CN¥14.9m (up 3.3% from 1Q 2024). Profit margin: 16% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
Guanhao Biotech Co.,Ltd., Annual General Meeting, May 13, 2025 Guanhao Biotech Co.,Ltd., Annual General Meeting, May 13, 2025, at 15:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Large one-off items impacting financial results. Announcement • Mar 31
Guanhao Biotech Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Guanhao Biotech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025 Announcement • Dec 31
Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 23, 2025 Guanhao Biotech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 23, 2025 Announcement • Nov 08
Beijing Century TianFu Venture Capital Centre (Limited Partnership) acquired 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. for CNY 85.4 million. Beijing Century TianFu Venture Capital Centre (Limited Partnership) acquired 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. for CNY 85.4 million on October 25, 2024.
Beijing Century TianFu Venture Capital Centre (Limited Partnership) completed the acquisition of 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. on October 25, 2024. Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.023 (vs CN¥0.04 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.023 (down from CN¥0.04 in 3Q 2023). Revenue: CN¥88.4m (down 9.9% from 3Q 2023). Net income: CN¥7.69m (down 27% from 3Q 2023). Profit margin: 8.7% (down from 11% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Guanhao Biotech Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Guanhao Biotech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.027 (vs CN¥0.037 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.027 (down from CN¥0.037 in 2Q 2023). Revenue: CN¥98.3m (flat on 2Q 2023). Net income: CN¥5.76m (down 33% from 2Q 2023). Profit margin: 5.9% (down from 8.8% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Announcement • Jun 29
Guanhao Biotech Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Guanhao Biotech Co.,Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.08 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.05 (down from CN¥0.08 in 1Q 2023). Revenue: CN¥91.4m (down 19% from 1Q 2023). Net income: CN¥14.4m (down 35% from 1Q 2023). Profit margin: 16% (down from 20% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥8.58, the stock trades at a trailing P/E ratio of 73.4x. Average trailing P/E is 35x in the Biotechs industry in China. Total loss to shareholders of 59% over the past three years. Announcement • Mar 30
Guanhao Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Guanhao Biotech Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 07
Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 26, 2024 Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 26, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China Agenda: To consider 2023 work report of the board of directors; to consider 2023 work report of the supervisory committee; to consider 2023 annual report and its summary; to consider 2023 annual accounts; to consider 2023 profit distribution plan; to consider Special audit statement on fund occupation by controlling shareholders and other related parties; and to consider other matters. Reported Earnings • Mar 06
Full year 2023 earnings released: EPS: CN¥0.12 (vs CN¥1.16 loss in FY 2022) Full year 2023 results: EPS: CN¥0.12 (up from CN¥1.16 loss in FY 2022). Revenue: CN¥404.2m (up 7.1% from FY 2022). Net income: CN¥31.0m (up CN¥338.8m from FY 2022). Profit margin: 7.7% (up from net loss in FY 2022). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Announcement • Dec 30
Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 06, 2024 Guanhao Biotech Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 06, 2024 New Risk • Oct 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.3% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.2% average weekly change). Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.046 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.04 (down from CN¥0.046 in 3Q 2022). Revenue: CN¥98.1m (up 7.7% from 3Q 2022). Net income: CN¥10.5m (down 15% from 3Q 2022). Profit margin: 11% (down from 14% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Aug 23
Second quarter 2023 earnings released: EPS: CN¥0.037 (vs CN¥1.03 loss in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.037 (up from CN¥1.03 loss in 2Q 2022). Revenue: CN¥98.1m (up 23% from 2Q 2022). Net income: CN¥8.63m (up CN¥274.4m from 2Q 2022). Profit margin: 8.8% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Jul 01
Guanhao Biotech Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023 Guanhao Biotech Co.,Ltd. announced that they will report first half, 2023 results on Aug 23, 2023 Announcement • Jun 27
Guanhao Biotech Co.,Ltd. Announces Management Appointments Guanhao Biotech Co.,Ltd. at its 2nd Extraordinary General Meeting of 2023 held on 21 June 2023 elected Deng Chao as independent director and Tian Dan as non-employee supervisors. Reported Earnings • Apr 22
Full year 2022 earnings released: CN¥1.16 loss per share (vs CN¥0.28 profit in FY 2021) Full year 2022 results: CN¥1.16 loss per share (down from CN¥0.28 profit in FY 2021). Revenue: CN¥377.3m (down 23% from FY 2021). Net loss: CN¥307.8m (down CN¥381.5m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Non-Employee Supervisor Li Jianhui is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.046 (vs CN¥0.08 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.046 (down from CN¥0.08 in 3Q 2021). Revenue: CN¥91.1m (down 17% from 3Q 2021). Net income: CN¥12.4m (down 37% from 3Q 2021). Profit margin: 14% (down from 18% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥11.46, the stock trades at a trailing P/E ratio of 43.7x. Average trailing P/E is 34x in the Biotechs industry in China. Total loss to shareholders of 51% over the past three years. Reported Earnings • Aug 26
Second quarter 2022 earnings released: CN¥1.03 loss per share (vs CN¥0.08 profit in 2Q 2021) Second quarter 2022 results: CN¥1.03 loss per share (down from CN¥0.08 profit in 2Q 2021). Revenue: CN¥79.9m (down 40% from 2Q 2021). Net loss: CN¥265.8m (down CN¥287.7m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥15.02, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years. Board Change • Apr 27
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Non-Employee Supervisor Li Jianhui is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 16
Guanhao Biotech Co.,Ltd., Annual General Meeting, May 18, 2022 Guanhao Biotech Co.,Ltd., Annual General Meeting, May 18, 2022, at 14:30 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee; to consider 2021 annual report and its summary; to consider 2021 annual accounts; to consider 2021 profit distribution plan; to consider Special audit statement on fund occupation by controlling shareholders and other related parties; to consider 2022 appointment of financial audit firm; and to consider other matters. Reported Earnings • Apr 16
First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.07 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.08 (up from CN¥0.07 in 1Q 2021). Revenue: CN¥122.9m (down 4.3% from 1Q 2021). Net income: CN¥21.8m (up 19% from 1Q 2021). Profit margin: 18% (up from 14% in 1Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 16
Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.04 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: CN¥109.6m (down 5.1% from 3Q 2020). Net income: CN¥19.6m (up 98% from 3Q 2020). Profit margin: 18% (up from 8.6% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.062 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥134.0m (up 22% from 2Q 2020). Net income: CN¥22.0m (up 43% from 2Q 2020). Profit margin: 16% (up from 14% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Reported Earnings • Apr 13
First quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.04 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥128.4m (up 38% from 1Q 2020). Net income: CN¥18.2m (up 58% from 1Q 2020). Profit margin: 14% (up from 12% in 1Q 2020). Announcement • Mar 10
Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 30, 2021 Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 30, 2021, at 14:30 China Standard Time. Agenda: To consider 2020 work report of the board of directors; to consider 2020 work report of the supervisory committee; to consider 2020 annual report and its summary; to consider 2020 annual accounts; to consider 2020 profit distribution plan; to consider special audit statement on fund occupation by controlling shareholders and other related parties; and to consider other matterrs. Is New 90 Day High Low • Mar 10
New 90-day low: CN¥18.95 The company is down 30% from its price of CN¥26.95 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Reported Earnings • Mar 09
Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥1.75 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: CN¥437.0m (flat on FY 2019). Net income: CN¥46.6m (up CN¥511.9m from FY 2019). Profit margin: 11% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has fallen by 89% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 08
New 90-day low: CN¥19.36 The company is down 19% from its price of CN¥24.00 on 10 November 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. Announcement • Jan 22
Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 09, 2021 Guanhao Biotech Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 09, 2021 Is New 90 Day High Low • Jan 13
New 90-day low: CN¥22.15 The company is down 14% from its price of CN¥25.85 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 15
New 90-day high: CN¥29.88 The company is up 25% from its price of CN¥23.90 on 16 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period. Is New 90 Day High Low • Nov 17
New 90-day high: CN¥29.30 The company is up 5.0% from its price of CN¥27.86 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 14% over the same period. Is New 90 Day High Low • Nov 02
New 90-day low: CN¥23.15 The company is down 33% from its price of CN¥34.55 on 04 August 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 21% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥442.5m, with earnings decreasing by CN¥471.6m from the prior year. Total revenue was CN¥438.7m over the last 12 months, down 6.6% from the prior year. Announcement • Oct 20
Guanhao Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020 Guanhao Biotech Co.,Ltd. announced that they will report Q3, 2020 results on Oct 27, 2020 Announcement • Sep 23
Guanhao Biotech Co.,Ltd. (SZSE:300238) intends to acquire 31% stake in ZY Therapeutics Inc. from U.S.TIANYOU CAPITAL CORP for $3.1 million. Guanhao Biotech Co.,Ltd. (SZSE:300238) agreed to acquire 31% stake in ZY Therapeutics Inc. from U.S.TIANYOU CAPITAL CORP for $3.1 million on September 19, 2019. Guanhao Biotech will pay to the seller $0.5 million of the equity transfer price, and undertake the investment payment to the ZY Therapeutics of $2.6 million. Post acquisition, Guanhao Biotech will hold 31% of the equity and U.S.TIANYOU CAPITAL will hold 29.73% stake in ZY Therapeutics. As of December 31, 2018, ZY Therapeutics reported total assets of $0.99 million, net assets of $0.91 million, revenue of $0.02 million and net loss of $0.87 million. The transaction has been approved in the 17th meeting of the 4th directorate of Guanhao Biotech. Announcement • Jul 17
Guanhao Biotech Co.,Ltd. to Report First Half, 2020 Results on Jul 21, 2020 Guanhao Biotech Co.,Ltd. announced that they will report first half, 2020 results on Jul 21, 2020